Methylprednisolone May Be Superior to Dexamethasone in COVID-19 : A Meta-Analysis of Randomized Controlled Trials
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
American journal of therapeutics - 29(2022), 3 vom: 02. Mai, Seite e351-e354 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Beran, Azizullah [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 11.05.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1097/MJT.0000000000001507 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340616946 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340616946 | ||
| 003 | DE-627 | ||
| 005 | 20231226005756.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/MJT.0000000000001507 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1135.xml |
| 035 | |a (DE-627)NLM340616946 | ||
| 035 | |a (NLM)35533325 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Beran, Azizullah |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Methylprednisolone May Be Superior to Dexamethasone in COVID-19 |b A Meta-Analysis of Randomized Controlled Trials |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.05.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 650 | 7 | |a Methylprednisolone |2 NLM | |
| 650 | 7 | |a X4W7ZR7023 |2 NLM | |
| 700 | 1 | |a Ayesh, Hazem |e verfasserin |4 aut | |
| 700 | 1 | |a Mhanna, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Srour, Omar |e verfasserin |4 aut | |
| 700 | 1 | |a Musallam, Rami |e verfasserin |4 aut | |
| 700 | 1 | |a Sayeh, Wasef |e verfasserin |4 aut | |
| 700 | 1 | |a Khokher, Waleed |e verfasserin |4 aut | |
| 700 | 1 | |a Altorok, Nehaya |e verfasserin |4 aut | |
| 700 | 1 | |a Noori, Zaid |e verfasserin |4 aut | |
| 700 | 1 | |a Assaly, Ragheb |e verfasserin |4 aut | |
| 700 | 1 | |a Altorok, Nezam |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of therapeutics |d 1994 |g 29(2022), 3 vom: 02. Mai, Seite e351-e354 |w (DE-627)NLM093845677 |x 1536-3686 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2022 |g number:3 |g day:02 |g month:05 |g pages:e351-e354 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/MJT.0000000000001507 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2022 |e 3 |b 02 |c 05 |h e351-e354 | ||